tubacin [Ligand Id: 7374] activity data from GtoPdb and ChEMBL
Click here for a description of the charts and data table
Please tell us if you are using this feature and what you think!
| ChEMBL ligand: CHEMBL356769 (Tubacin) |
|---|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
| DB | Assay description | Assay Type | Standard value | Standard parameter | Original value | Original units | Original parameter | Reference |
|---|---|---|---|---|---|---|---|---|
| Aspartyl/asparaginyl beta-hydroxylase in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4680030] [UniProtKB: Q12797] | ||||||||
| ChEMBL | Inhibition of N-His6-tagged human AspH (315-755) expressed in Escherichia coli BL21 (DE3) using 1 uM hFX-CP as substrate mixture with high 200 uM 2OG, 100 uM L-ascorbic acid and 2 uM FAS incubated for 35 mins by MS analysis | B | 5.24 | pIC50 | 5690 | nM | IC50 | Bioorg Med Chem (2020) 28: 115675-115675 [PMID:33069066] |
| ChEMBL | Inhibition of N-His6-tagged human AspH (315-755) expressed in Escherichia coli BL21 (DE3) using 1 uM hFX-CP as substrate mixture with 3 uM 2OG, 100 uM L-ascorbic acid and high 20 uM FAS incubated for 35 mins by MS analysis | B | 5.31 | pIC50 | 4910 | nM | IC50 | Bioorg Med Chem (2020) 28: 115675-115675 [PMID:33069066] |
| ChEMBL | Inhibition of N-His6-tagged human AspH (315-755) expressed in Escherichia coli BL21 (DE3) using 1 uM hFX-CP as substrate mixture with 3 uM 2OG, 100 uM L-ascorbic acid and 2 uM FAS incubated for 35 mins by MS analysis | B | 5.39 | pIC50 | 4120 | nM | IC50 | Bioorg Med Chem (2020) 28: 115675-115675 [PMID:33069066] |
| ChEMBL | Inhibition of N-His6-tagged human AspH (315-755) expressed in Escherichia coli BL21 (DE3) using high 10 uM hFX-CP as substrate mixture with 10 uM 2OG, 100 uM L-ascorbic acid and 2 uM FAS incubated for 35 mins by MS analysis | B | 5.45 | pIC50 | 3570 | nM | IC50 | Bioorg Med Chem (2020) 28: 115675-115675 [PMID:33069066] |
| histone deacetylase 1/Histone deacetylase 1 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL325] [GtoPdb: 2658] [UniProtKB: Q13547] | ||||||||
| ChEMBL | Inhibition of HDAC1 | B | 6 | pKi | 995 | nM | Ki | J Med Chem (2008) 51: 2898-2906 [PMID:18412327] |
| ChEMBL | Inhibition of human HDAC1 | B | 6.49 | pKi | 326.4 | nM | Ki | Bioorg Med Chem (2015) 23: 5151-5155 [PMID:25637120] |
| ChEMBL | Inhibition of human HDAC1 | B | 7.55 | pKi | 28 | nM | Ki | Nat Chem Biol (2010) 6: 238-243 [PMID:20139990] |
| ChEMBL | HDAC Activity Assay: HDAC assay is performed using fluorescently-labeled acetylated substrate, which comprises an acetylated lysine side chain. After incubation with HDAC, deacetylation of the substrate sensitizes the substrate such that, in a second step, treatment with the detection enzyme produces a fluorophore. HDACs 1 and 6 were expressed as full length fusion proteins. Purified proteins were incubated with 50 μM fluorescently-labeled acetylated peptide substrate and test compound for 2 hours at RT in HDAC assay buffer containing 50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1% DMSO, and 1% BSA. Reactions were terminated by the addition of the Developer after 2 hours, and the development of fluorescence signal, which was relative to the amount of deacetylated peptide, was monitored by time-course measurement of EnVision (PerkinElmer). The HDAC activity was estimated from the slope of time-course measurement of the fluorescence intensity. | B | 4.79 | pIC50 | 16400 | nM | IC50 | US-9249087-B2. HDAC inhibitors and therapeutic methods using the same (2016) |
| ChEMBL | Inhibition of human recombinant HDAC1 protein using RHKKAc from p53 as substrate | B | 5.85 | pIC50 | 1400 | nM | IC50 | J Med Chem (2013) 56: 6297-6313 [PMID:23627282] |
| ChEMBL | Inhibition of human recombinant HDAC1 using RHKKAc as substrate | B | 5.85 | pIC50 | 1400 | nM | IC50 | J Med Chem (2013) 56: 7201-7211 [PMID:23964961] |
| ChEMBL | Inhibition of full length GST-tagged human HDAC1 using Arg-His-Lys-Lys(Ac) substrate incubated for 2 hrs by fluorescence assay | B | 5.85 | pIC50 | 1400 | nM | IC50 | Bioorg Med Chem Lett (2014) 24: 5450-5454 [PMID:25454270] |
| ChEMBL | Inhibition of HADC1 (unknown origin) | B | 5.85 | pIC50 | 1400 | nM | IC50 | J Med Chem (2020) 63: 23-39 [PMID:31415174] |
| ChEMBL | Inhibition of HDAC1 (unknown origin) | B | 5.85 | pIC50 | 1400 | nM | IC50 | Eur J Med Chem (2021) 221: 113526-113526 [PMID:33992929] |
| ChEMBL | Inhibition of recombinant human HDAC1 using RHKKAc fluorogenic peptide substrate | B | 5.85 | pIC50 | 1400 | nM | IC50 | J Med Chem (2019) 62: 1138-1166 [PMID:30645113] |
| ChEMBL | Inhibition of recombinant C-terminal His/FLAG-tagged human HDAC1 expressed in baculovirus expression system using fluorogenic ZMAL as substrate incubated for 90 mins by fluorescence assay | B | 6 | pIC50 | 1010 | nM | IC50 | J Med Chem (2019) 62: 1138-1166 [PMID:30645113] |
| ChEMBL | Inhibition of HDAC1 | B | 6.62 | pIC50 | 240 | nM | IC50 | Bioorg Med Chem (2010) 18: 4103-4110 [PMID:20472442] |
| histone deacetylase 10/Histone deacetylase 10 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL5103] [GtoPdb: 2614] [UniProtKB: Q969S8] | ||||||||
| ChEMBL | Inhibition of human HDAC10 | B | 6.43 | pKi | 373.7 | nM | Ki | Bioorg Med Chem (2015) 23: 5151-5155 [PMID:25637120] |
| ChEMBL | HDAC Activity Assay: HDAC assay is performed using fluorescently-labeled acetylated substrate, which comprises an acetylated lysine side chain. After incubation with HDAC, deacetylation of the substrate sensitizes the substrate such that, in a second step, treatment with the detection enzyme produces a fluorophore. HDACs 1 and 6 were expressed as full length fusion proteins. Purified proteins were incubated with 50 μM fluorescently-labeled acetylated peptide substrate and test compound for 2 hours at RT in HDAC assay buffer containing 50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1% DMSO, and 1% BSA. Reactions were terminated by the addition of the Developer after 2 hours, and the development of fluorescence signal, which was relative to the amount of deacetylated peptide, was monitored by time-course measurement of EnVision (PerkinElmer). The HDAC activity was estimated from the slope of time-course measurement of the fluorescence intensity. | B | 4.52 | pIC50 | >30000 | nM | IC50 | US-9249087-B2. HDAC inhibitors and therapeutic methods using the same (2016) |
| ChEMBL | Inhibition of human recombinant HDAC10 protein using RHKKAc from p53 as substrate | B | 5.43 | pIC50 | 3710 | nM | IC50 | J Med Chem (2013) 56: 6297-6313 [PMID:23627282] |
| ChEMBL | Inhibition of human recombinant HDAC10 using RHKKAc as substrate | B | 5.43 | pIC50 | 3710 | nM | IC50 | J Med Chem (2013) 56: 7201-7211 [PMID:23964961] |
| ChEMBL | Inhibition of N-terminal GST-tagged human HDAC10 (1 to 481 residues) using Arg-His-Lys-Lys(Ac) substrate incubated for 2 hrs by fluorescence assay | B | 5.43 | pIC50 | 3710 | nM | IC50 | Bioorg Med Chem Lett (2014) 24: 5450-5454 [PMID:25454270] |
| ChEMBL | Inhibition of HDAC10 (unknown origin) | B | 5.43 | pIC50 | 3710 | nM | IC50 | Eur J Med Chem (2021) 221: 113526-113526 [PMID:33992929] |
| histone deacetylase 11/Histone deacetylase 11 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3310] [GtoPdb: 2615] [UniProtKB: Q96DB2] | ||||||||
| ChEMBL | Inhibition of human HDAC11 | B | 6.14 | pKi | 718.7 | nM | Ki | Bioorg Med Chem (2015) 23: 5151-5155 [PMID:25637120] |
| ChEMBL | HDAC Activity Assay: HDAC assay is performed using fluorescently-labeled acetylated substrate, which comprises an acetylated lysine side chain. After incubation with HDAC, deacetylation of the substrate sensitizes the substrate such that, in a second step, treatment with the detection enzyme produces a fluorophore. HDACs 1 and 6 were expressed as full length fusion proteins. Purified proteins were incubated with 50 μM fluorescently-labeled acetylated peptide substrate and test compound for 2 hours at RT in HDAC assay buffer containing 50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1% DMSO, and 1% BSA. Reactions were terminated by the addition of the Developer after 2 hours, and the development of fluorescence signal, which was relative to the amount of deacetylated peptide, was monitored by time-course measurement of EnVision (PerkinElmer). The HDAC activity was estimated from the slope of time-course measurement of the fluorescence intensity. | B | 4.52 | pIC50 | >30000 | nM | IC50 | US-9249087-B2. HDAC inhibitors and therapeutic methods using the same (2016) |
| ChEMBL | Inhibition of human recombinant HDAC11 protein using RHKKAc from p53 as substrate | B | 5.42 | pIC50 | 3790 | nM | IC50 | J Med Chem (2013) 56: 6297-6313 [PMID:23627282] |
| ChEMBL | Inhibition of human recombinant HDAC11 using RHKKAc as substrate | B | 5.42 | pIC50 | 3790 | nM | IC50 | J Med Chem (2013) 56: 7201-7211 [PMID:23964961] |
| ChEMBL | Inhibition of full length N-terminal GST-tagged human HDAC11 using Arg-His-Lys-Lys(Ac) substrate incubated for 2 hrs by fluorescence assay | B | 5.42 | pIC50 | 3790 | nM | IC50 | Bioorg Med Chem Lett (2014) 24: 5450-5454 [PMID:25454270] |
| ChEMBL | Inhibition of HDAC11 (unknown origin) | B | 5.42 | pIC50 | 3790 | nM | IC50 | Eur J Med Chem (2021) 221: 113526-113526 [PMID:33992929] |
| histone deacetylase 2/Histone deacetylase 2 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1937] [GtoPdb: 2616] [UniProtKB: Q92769] | ||||||||
| ChEMBL | Inhibition of human HDAC2 | B | 5.93 | pKi | 1180.7 | nM | Ki | Bioorg Med Chem (2015) 23: 5151-5155 [PMID:25637120] |
| ChEMBL | Inhibition of human HDAC2 | B | 7.38 | pKi | 42 | nM | Ki | Nat Chem Biol (2010) 6: 238-243 [PMID:20139990] |
| ChEMBL | HDAC Activity Assay: HDAC assay is performed using fluorescently-labeled acetylated substrate, which comprises an acetylated lysine side chain. After incubation with HDAC, deacetylation of the substrate sensitizes the substrate such that, in a second step, treatment with the detection enzyme produces a fluorophore. HDACs 1 and 6 were expressed as full length fusion proteins. Purified proteins were incubated with 50 μM fluorescently-labeled acetylated peptide substrate and test compound for 2 hours at RT in HDAC assay buffer containing 50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1% DMSO, and 1% BSA. Reactions were terminated by the addition of the Developer after 2 hours, and the development of fluorescence signal, which was relative to the amount of deacetylated peptide, was monitored by time-course measurement of EnVision (PerkinElmer). The HDAC activity was estimated from the slope of time-course measurement of the fluorescence intensity. | B | 4.52 | pIC50 | >30000 | nM | IC50 | US-9249087-B2. HDAC inhibitors and therapeutic methods using the same (2016) |
| ChEMBL | Inhibition of human recombinant HDAC2 protein using RHKKAc from p53 as substrate | B | 5.2 | pIC50 | 6270 | nM | IC50 | J Med Chem (2013) 56: 6297-6313 [PMID:23627282] |
| ChEMBL | Inhibition of human recombinant HDAC2 using RHKKAc as substrate | B | 5.2 | pIC50 | 6270 | nM | IC50 | J Med Chem (2013) 56: 7201-7211 [PMID:23964961] |
| ChEMBL | Inhibition of full length C-terminal 6x-His tagged human HDAC2 using Arg-His-Lys-Lys(Ac) substrate incubated for 2 hrs by fluorescence assay | B | 5.2 | pIC50 | 6270 | nM | IC50 | Bioorg Med Chem Lett (2014) 24: 5450-5454 [PMID:25454270] |
| ChEMBL | Inhibition of HDAC2 (unknown origin) | B | 5.2 | pIC50 | 6270 | nM | IC50 | Eur J Med Chem (2021) 221: 113526-113526 [PMID:33992929] |
| ChEMBL | Inhibition of HADC2 (unknown origin) | B | 5.2 | pIC50 | 6270 | nM | IC50 | J Med Chem (2020) 63: 23-39 [PMID:31415174] |
| ChEMBL | Inhibition of HDAC2 | B | 6.59 | pIC50 | 260 | nM | IC50 | Bioorg Med Chem (2010) 18: 4103-4110 [PMID:20472442] |
| histone deacetylase 3/Histone deacetylase 3 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1829] [GtoPdb: 2617] [UniProtKB: O15379] | ||||||||
| ChEMBL | Inhibition of human HDAC3 | B | 6.26 | pKi | 544.3 | nM | Ki | Bioorg Med Chem (2015) 23: 5151-5155 [PMID:25637120] |
| ChEMBL | Inhibition of human HDAC3 | B | 6.56 | pKi | 275 | nM | Ki | Nat Chem Biol (2010) 6: 238-243 [PMID:20139990] |
| ChEMBL | Inhibition of full length C-terminal 6x-His tagged human HDAC3 using Arg-His-Lys-Lys(Ac) substrate incubated for 2 hrs by fluorescence assay | B | 5.9 | pIC50 | 1270 | nM | IC50 | Bioorg Med Chem Lett (2014) 24: 5450-5454 [PMID:25454270] |
| ChEMBL | Inhibition of HADC3 (unknown origin) | B | 5.9 | pIC50 | 1270 | nM | IC50 | J Med Chem (2020) 63: 23-39 [PMID:31415174] |
| ChEMBL | Inhibition of HDAC3 (unknown origin) | B | 5.9 | pIC50 | 1270 | nM | IC50 | Eur J Med Chem (2021) 221: 113526-113526 [PMID:33992929] |
| ChEMBL | Inhibition of HDAC3 | B | 6.2 | pIC50 | 630 | nM | IC50 | Bioorg Med Chem (2010) 18: 4103-4110 [PMID:20472442] |
| histone deacetylase 3/Histone deacetylase 3/Nuclear receptor corepressor 2 (HDAC3/NCoR2) in Human (target type: PROTEIN COMPLEX) [ChEMBL: CHEMBL2111363] [GtoPdb: 2617] [UniProtKB: O15379, Q9Y618] | ||||||||
| ChEMBL | HDAC Activity Assay: HDAC assay is performed using fluorescently-labeled acetylated substrate, which comprises an acetylated lysine side chain. After incubation with HDAC, deacetylation of the substrate sensitizes the substrate such that, in a second step, treatment with the detection enzyme produces a fluorophore. HDACs 1 and 6 were expressed as full length fusion proteins. Purified proteins were incubated with 50 μM fluorescently-labeled acetylated peptide substrate and test compound for 2 hours at RT in HDAC assay buffer containing 50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1% DMSO, and 1% BSA. Reactions were terminated by the addition of the Developer after 2 hours, and the development of fluorescence signal, which was relative to the amount of deacetylated peptide, was monitored by time-course measurement of EnVision (PerkinElmer). The HDAC activity was estimated from the slope of time-course measurement of the fluorescence intensity. | B | 4.52 | pIC50 | >30000 | nM | IC50 | US-9249087-B2. HDAC inhibitors and therapeutic methods using the same (2016) |
| ChEMBL | Inhibition of HDAC3/NcoR2 (unknown origin) using RHKKAc from p53 as substrate | B | 5.9 | pIC50 | 1270 | nM | IC50 | J Med Chem (2013) 56: 6297-6313 [PMID:23627282] |
| ChEMBL | Inhibition of HDAC3/NcoR2 (unknown origin) using RHKKAc as substrate | B | 5.9 | pIC50 | 1270 | nM | IC50 | J Med Chem (2013) 56: 7201-7211 [PMID:23964961] |
| histone deacetylase 4/Histone deacetylase 4 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3524] [GtoPdb: 2659] [UniProtKB: P56524] | ||||||||
| ChEMBL | Inhibition of human HDAC4 | B | 4.77 | pKi | 17000 | nM | Ki | Nat Chem Biol (2010) 6: 238-243 [PMID:20139990] |
| ChEMBL | Inhibition of human HDAC4 | B | 5.04 | pKi | 9124.2 | nM | Ki | Bioorg Med Chem (2015) 23: 5151-5155 [PMID:25637120] |
| ChEMBL | HDAC Activity Assay: HDAC assay is performed using fluorescently-labeled acetylated substrate, which comprises an acetylated lysine side chain. After incubation with HDAC, deacetylation of the substrate sensitizes the substrate such that, in a second step, treatment with the detection enzyme produces a fluorophore. HDACs 1 and 6 were expressed as full length fusion proteins. Purified proteins were incubated with 50 μM fluorescently-labeled acetylated peptide substrate and test compound for 2 hours at RT in HDAC assay buffer containing 50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1% DMSO, and 1% BSA. Reactions were terminated by the addition of the Developer after 2 hours, and the development of fluorescence signal, which was relative to the amount of deacetylated peptide, was monitored by time-course measurement of EnVision (PerkinElmer). The HDAC activity was estimated from the slope of time-course measurement of the fluorescence intensity. | B | 4.52 | pIC50 | >30000 | nM | IC50 | US-9249087-B2. HDAC inhibitors and therapeutic methods using the same (2016) |
| ChEMBL | Inhibition of human recombinant HDAC4 protein using Acetyl-Lys (trifluoroacetyl)-AMC as substrate | B | 4.76 | pIC50 | 17300 | nM | IC50 | J Med Chem (2013) 56: 6297-6313 [PMID:23627282] |
| ChEMBL | Inhibition of human recombinant HDAC4 using acetyl-Lys(trifluoroacetyl)-AMC as substrate | B | 4.76 | pIC50 | 17300 | nM | IC50 | J Med Chem (2013) 56: 7201-7211 [PMID:23964961] |
| ChEMBL | Inhibition of N-terminal GST-tagged human HDAC4 (627 to 1085 residues) using fluorogenic acetyl-Lys(trifluoroacetyl)-AMC substrate incubated for 2 hrs by fluorescence assay | B | 4.76 | pIC50 | 17300 | nM | IC50 | Bioorg Med Chem Lett (2014) 24: 5450-5454 [PMID:25454270] |
| ChEMBL | Inhibition of HDAC4 (unknown origin) | B | 4.76 | pIC50 | 17300 | nM | IC50 | Eur J Med Chem (2021) 221: 113526-113526 [PMID:33992929] |
| histone deacetylase 5/Histone deacetylase 5 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2563] [GtoPdb: 2660] [UniProtKB: Q9UQL6] | ||||||||
| ChEMBL | Inhibition of human HDAC5 | B | 5.72 | pKi | 1919.6 | nM | Ki | Bioorg Med Chem (2015) 23: 5151-5155 [PMID:25637120] |
| ChEMBL | Inhibition of human HDAC5 | B | 5.82 | pKi | 1500 | nM | Ki | Nat Chem Biol (2010) 6: 238-243 [PMID:20139990] |
| ChEMBL | HDAC Activity Assay: HDAC assay is performed using fluorescently-labeled acetylated substrate, which comprises an acetylated lysine side chain. After incubation with HDAC, deacetylation of the substrate sensitizes the substrate such that, in a second step, treatment with the detection enzyme produces a fluorophore. HDACs 1 and 6 were expressed as full length fusion proteins. Purified proteins were incubated with 50 μM fluorescently-labeled acetylated peptide substrate and test compound for 2 hours at RT in HDAC assay buffer containing 50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1% DMSO, and 1% BSA. Reactions were terminated by the addition of the Developer after 2 hours, and the development of fluorescence signal, which was relative to the amount of deacetylated peptide, was monitored by time-course measurement of EnVision (PerkinElmer). The HDAC activity was estimated from the slope of time-course measurement of the fluorescence intensity. | B | 4.52 | pIC50 | >30000 | nM | IC50 | US-9249087-B2. HDAC inhibitors and therapeutic methods using the same (2016) |
| ChEMBL | Inhibition of human recombinant HDAC5 protein using Acetyl-Lys (trifluoroacetyl)-AMC as substrate | B | 5.47 | pIC50 | 3350 | nM | IC50 | J Med Chem (2013) 56: 6297-6313 [PMID:23627282] |
| ChEMBL | Inhibition of human recombinant HDAC5 using acetyl-Lys(trifluoroacetyl)-AMC as substrate | B | 5.47 | pIC50 | 3350 | nM | IC50 | J Med Chem (2013) 56: 7201-7211 [PMID:23964961] |
| ChEMBL | Inhibition of C-terminal 6x-His tagged human HDAC5 (657 to 1123 residues) using fluorogenic acetyl-Lys(trifluoroacetyl)-AMC substrate incubated for 2 hrs by fluorescence assay | B | 5.47 | pIC50 | 3350 | nM | IC50 | Bioorg Med Chem Lett (2014) 24: 5450-5454 [PMID:25454270] |
| ChEMBL | Inhibition of HDAC5 (unknown origin) | B | 5.47 | pIC50 | 3350 | nM | IC50 | Eur J Med Chem (2021) 221: 113526-113526 [PMID:33992929] |
| histone deacetylase 6/Histone deacetylase 6 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1865] [GtoPdb: 2618] [UniProtKB: Q9UBN7] | ||||||||
| ChEMBL | Inhibition of HDAC6 | B | 6.85 | pKi | 142 | nM | Ki | J Med Chem (2008) 51: 2898-2906 [PMID:18412327] |
| ChEMBL | Inhibition of human HDAC6 | B | 7.8 | pKi | 16 | nM | Ki | Nat Chem Biol (2010) 6: 238-243 [PMID:20139990] |
| ChEMBL | Inhibition of human HDAC6 | B | 9.05 | pKi | 0.9 | nM | Ki | Bioorg Med Chem (2015) 23: 5151-5155 [PMID:25637120] |
| ChEMBL | Inhibition of HDAC6 in human HeLa cells assessed as reduction in K40 hyperacetylation of alpha-tubulin incubated for 6 hrs by immunofluorescence assay | B | 5.54 | pIC50 | 2900 | nM | IC50 | Bioorg Med Chem Lett (2014) 24: 5450-5454 [PMID:25454270] |
| ChEMBL | Inhibition of HDAC6 in human HeLa cells using acetyl tubulin as substrate assessed as Ac-Lys accumulation in nuclear histones after 6 hrs by immunofluorescence assay | B | 5.54 | pIC50 | 2900 | nM | IC50 | J Med Chem (2013) 56: 7201-7211 [PMID:23964961] |
| ChEMBL | Inhibition of full length human HDAC6 using FAM-labeled acetylated peptide as substrate by electrophoretic mobility shift assay | B | 5.8 | pIC50 | 1600 | nM | IC50 | J Med Chem (2021) 64: 2691-2704 [PMID:33576627] |
| ChEMBL | HDAC Activity Assay: HDAC assay is performed using fluorescently-labeled acetylated substrate, which comprises an acetylated lysine side chain. After incubation with HDAC, deacetylation of the substrate sensitizes the substrate such that, in a second step, treatment with the detection enzyme produces a fluorophore. HDACs 1 and 6 were expressed as full length fusion proteins. Purified proteins were incubated with 50 μM fluorescently-labeled acetylated peptide substrate and test compound for 2 hours at RT in HDAC assay buffer containing 50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1% DMSO, and 1% BSA. Reactions were terminated by the addition of the Developer after 2 hours, and the development of fluorescence signal, which was relative to the amount of deacetylated peptide, was monitored by time-course measurement of EnVision (PerkinElmer). The HDAC activity was estimated from the slope of time-course measurement of the fluorescence intensity. | B | 7.82 | pIC50 | 15 | nM | IC50 | US-9249087-B2. HDAC inhibitors and therapeutic methods using the same (2016) |
| ChEMBL | Inhibition of HDAC6 | B | 7.89 | pIC50 | 13 | nM | IC50 | Bioorg Med Chem (2010) 18: 4103-4110 [PMID:20472442] |
| ChEMBL | Inhibition of recombinant human HDAC6 using Boc-Lys(Ac)-AMC as substrate pre-incubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence based assay | B | 8.07 | pIC50 | 8.5 | nM | IC50 | J Med Chem (2021) 64: 2186-2204 [PMID:33570940] |
| ChEMBL | Inhibition of recombinant N-terminal GST-tagged human HDAC6 expressed in baculovirus expression system using fluorogenic ZMAL as substrate incubated for 90 mins by fluorescence assay | B | 8.15 | pIC50 | 7 | nM | IC50 | J Med Chem (2019) 62: 1138-1166 [PMID:30645113] |
| ChEMBL | Inhibition of HDAC6 (unknown origin) | B | 8.4 | pIC50 | 4 | nM | IC50 | Eur J Med Chem (2018) 150: 506-524 [PMID:29549837] |
| ChEMBL | Inhibition of HADC6 (unknown origin) | B | 8.4 | pIC50 | 4 | nM | IC50 | J Med Chem (2020) 63: 23-39 [PMID:31415174] |
| ChEMBL | Inhibition of human HDAC6 using (Z-(Ac)Lys-AMC) as substrate after 90 mins by fluorescence analysis | B | 8.4 | pIC50 | 4 | nM | IC50 | Eur J Med Chem (2019) 162: 321-333 [PMID:30448419] |
| ChEMBL | Inhibition of recombinant human HDAC6 using RHKKAc fluorogenic peptide substrate | B | 8.4 | pIC50 | 4 | nM | IC50 | J Med Chem (2019) 62: 1138-1166 [PMID:30645113] |
| ChEMBL | Inhibition of HDAC6 (unknown origin) | B | 8.4 | pIC50 | 4 | nM | IC50 | Eur J Med Chem (2021) 221: 113526-113526 [PMID:33992929] |
| ChEMBL | Inhibition of recombinant N-GST-tagged HDAC6 (unknown origin) assessed as reduction in deacetylation of Ac-Arg-Gly-Lys(Ac)-AMC substrate by fluorescence assay | B | 8.4 | pIC50 | 4 | nM | IC50 | Bioorg Med Chem Lett (2014) 24: 5450-5454 [PMID:25454270] |
| ChEMBL | Inhibition of human recombinant HDAC6 protein using RHKKAc from p53 as substrate | B | 8.4 | pIC50 | 4 | nM | IC50 | J Med Chem (2013) 56: 6297-6313 [PMID:23627282] |
| ChEMBL | Inhibition of human recombinant HDAC6 using RHKKAc as substrate | B | 8.4 | pIC50 | 4 | nM | IC50 | J Med Chem (2013) 56: 7201-7211 [PMID:23964961] |
| GtoPdb | - | - | 8.4 | pIC50 | 4 | nM | IC50 | Proc Natl Acad Sci USA (2003) 100: 4389-94 [PMID:12677000] |
| ChEMBL | Tested for inhibition of Histone deacetylase 6 induced acetylated tubulin in mammalian cells. | B | 5.54 | pEC50 | 2900 | nM | EC50 | J Med Chem (2003) 46: 4826-4829 [PMID:14584932] |
| ChEMBL | Inhibition of HDAC6 in human A549 cells assessed as induction of alpha-tubulin acetylation by fluorescence microscopy | B | 5.54 | pEC50 | 2900 | nM | EC50 | Nat Chem Biol (2005) 1: 74-84 [PMID:16408003] |
| ChEMBL | Inhibition of HDAC-6 in human A549 cells assessed as induction of alpha-tubulin acetylation after 20 hrs by cytoblot analysis | B | 5.6 | pEC50 | 2500 | nM | EC50 | Medchemcomm (2012) 3: 135-161 |
| histone deacetylase 7/Histone deacetylase 7 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2716] [GtoPdb: 2661] [UniProtKB: Q8WUI4] | ||||||||
| ChEMBL | Inhibition of human HDAC7 | B | 5.07 | pKi | 8500 | nM | Ki | Nat Chem Biol (2010) 6: 238-243 [PMID:20139990] |
| ChEMBL | Inhibition of human HDAC7 | B | 5.27 | pKi | 5426.9 | nM | Ki | Bioorg Med Chem (2015) 23: 5151-5155 [PMID:25637120] |
| ChEMBL | HDAC Activity Assay: HDAC assay is performed using fluorescently-labeled acetylated substrate, which comprises an acetylated lysine side chain. After incubation with HDAC, deacetylation of the substrate sensitizes the substrate such that, in a second step, treatment with the detection enzyme produces a fluorophore. HDACs 1 and 6 were expressed as full length fusion proteins. Purified proteins were incubated with 50 μM fluorescently-labeled acetylated peptide substrate and test compound for 2 hours at RT in HDAC assay buffer containing 50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1% DMSO, and 1% BSA. Reactions were terminated by the addition of the Developer after 2 hours, and the development of fluorescence signal, which was relative to the amount of deacetylated peptide, was monitored by time-course measurement of EnVision (PerkinElmer). The HDAC activity was estimated from the slope of time-course measurement of the fluorescence intensity. | B | 4.52 | pIC50 | >30000 | nM | IC50 | US-9249087-B2. HDAC inhibitors and therapeutic methods using the same (2016) |
| ChEMBL | Inhibition of human recombinant HDAC7 protein using Acetyl-Lys (trifluoroacetyl)-AMC as substrate | B | 5.01 | pIC50 | 9700 | nM | IC50 | J Med Chem (2013) 56: 6297-6313 [PMID:23627282] |
| ChEMBL | Inhibition of human recombinant HDAC7 using acetyl-Lys(trifluoroacetyl)-AMC as substrate | B | 5.01 | pIC50 | 9700 | nM | IC50 | J Med Chem (2013) 56: 7201-7211 [PMID:23964961] |
| ChEMBL | Inhibition of N-terminal GST-tagged human HDAC7 (518 to end residues) using fluorogenic acetyl-Lys(trifluoroacetyl)-AMC substrate incubated for 2 hrs by fluorescence assay | B | 5.01 | pIC50 | 9700 | nM | IC50 | Bioorg Med Chem Lett (2014) 24: 5450-5454 [PMID:25454270] |
| ChEMBL | Inhibition of HDAC7 (unknown origin) | B | 5.01 | pIC50 | 9700 | nM | IC50 | Eur J Med Chem (2021) 221: 113526-113526 [PMID:33992929] |
| histone deacetylase 8/Histone deacetylase 8 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3192] [GtoPdb: 2619] [UniProtKB: Q9BY41] | ||||||||
| ChEMBL | Activity of human HDAC8 | B | 6.77 | pKi | 170 | nM | Ki | Nat Chem Biol (2010) 6: 238-243 [PMID:20139990] |
| ChEMBL | Inhibition of human HDAC8 | B | 6.84 | pKi | 143.1 | nM | Ki | Bioorg Med Chem (2015) 23: 5151-5155 [PMID:25637120] |
| ChEMBL | Inhibition of HDAC8 | B | 5.3 | pIC50 | 5000 | nM | IC50 | Bioorg Med Chem (2010) 18: 4103-4110 [PMID:20472442] |
| ChEMBL | Inhibition of human recombinant HDAC8 protein using RHKAcKAc from p53 as substrate | B | 5.9 | pIC50 | 1270 | nM | IC50 | J Med Chem (2013) 56: 6297-6313 [PMID:23627282] |
| ChEMBL | Inhibition of human recombinant HDAC8 using RHKAcKAc as substrate | B | 5.9 | pIC50 | 1270 | nM | IC50 | J Med Chem (2013) 56: 7201-7211 [PMID:23964961] |
| ChEMBL | Inhibition of full length C-terminal 6x-His tagged human HDAC8 using Arg-His-Lys(Ac)-Lys(Ac) substrate incubated for 2 hrs by fluorescence assay | B | 5.9 | pIC50 | 1270 | nM | IC50 | Bioorg Med Chem Lett (2014) 24: 5450-5454 [PMID:25454270] |
| ChEMBL | Inhibition of HDAC8 (unknown origin) | B | 5.9 | pIC50 | 1270 | nM | IC50 | Eur J Med Chem (2021) 221: 113526-113526 [PMID:33992929] |
| ChEMBL | Inhibition of HADC8 (unknown origin) | B | 5.9 | pIC50 | 1270 | nM | IC50 | J Med Chem (2020) 63: 23-39 [PMID:31415174] |
| ChEMBL | HDAC Activity Assay: HDAC assay is performed using fluorescently-labeled acetylated substrate, which comprises an acetylated lysine side chain. After incubation with HDAC, deacetylation of the substrate sensitizes the substrate such that, in a second step, treatment with the detection enzyme produces a fluorophore. HDACs 1 and 6 were expressed as full length fusion proteins. Purified proteins were incubated with 50 μM fluorescently-labeled acetylated peptide substrate and test compound for 2 hours at RT in HDAC assay buffer containing 50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1% DMSO, and 1% BSA. Reactions were terminated by the addition of the Developer after 2 hours, and the development of fluorescence signal, which was relative to the amount of deacetylated peptide, was monitored by time-course measurement of EnVision (PerkinElmer). The HDAC activity was estimated from the slope of time-course measurement of the fluorescence intensity. | B | 6.07 | pIC50 | 854 | nM | IC50 | US-9249087-B2. HDAC inhibitors and therapeutic methods using the same (2016) |
| histone deacetylase 9/Histone deacetylase 9 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4145] [GtoPdb: 2620] [UniProtKB: Q9UKV0] | ||||||||
| ChEMBL | Inhibition of HDAC9 | B | 5.2 | pKi | 6300 | nM | Ki | J Med Chem (2008) 51: 2898-2906 [PMID:18412327] |
| ChEMBL | Inhibition of human HDAC9 | B | 6.29 | pKi | 509.3 | nM | Ki | Bioorg Med Chem (2015) 23: 5151-5155 [PMID:25637120] |
| ChEMBL | HDAC Activity Assay: HDAC assay is performed using fluorescently-labeled acetylated substrate, which comprises an acetylated lysine side chain. After incubation with HDAC, deacetylation of the substrate sensitizes the substrate such that, in a second step, treatment with the detection enzyme produces a fluorophore. HDACs 1 and 6 were expressed as full length fusion proteins. Purified proteins were incubated with 50 μM fluorescently-labeled acetylated peptide substrate and test compound for 2 hours at RT in HDAC assay buffer containing 50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1% DMSO, and 1% BSA. Reactions were terminated by the addition of the Developer after 2 hours, and the development of fluorescence signal, which was relative to the amount of deacetylated peptide, was monitored by time-course measurement of EnVision (PerkinElmer). The HDAC activity was estimated from the slope of time-course measurement of the fluorescence intensity. | B | 4.52 | pIC50 | >30000 | nM | IC50 | US-9249087-B2. HDAC inhibitors and therapeutic methods using the same (2016) |
| ChEMBL | Inhibition of human recombinant HDAC9 protein using Acetyl-Lys (trifluoroacetyl)-AMC as substrate | B | 5.37 | pIC50 | 4310 | nM | IC50 | J Med Chem (2013) 56: 6297-6313 [PMID:23627282] |
| ChEMBL | Inhibition of HDAC9 (unknown origin) | B | 5.37 | pIC50 | 4310 | nM | IC50 | Eur J Med Chem (2021) 221: 113526-113526 [PMID:33992929] |
| Histone deacetylase HD2 in Zea mays (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4919] [UniProtKB: Q94F81] | ||||||||
| ChEMBL | Inhibitory concentration against maize histone deacetylase 2 | B | 5.7 | pIC50 | 2000 | nM | IC50 | J Med Chem (2005) 48: 3344-3353 [PMID:15857140] |
| Leukotriene A4 hydrolase/Leukotriene A4 hydrolase in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4618] [GtoPdb: 1395] [UniProtKB: P09960] | ||||||||
| ChEMBL | Inhibition of recombinant human LTA4H Epoxide Hydrolase expressed in Escherichia coli BL21 (DE3) pLysS preincubated for 10 mins followed by addition of LTA4 as substrate measured after 15 mins by reverse-phase HPLC analysis | B | 5 | pIC50 | >10000 | nM | IC50 | J Med Chem (2017) 60: 1817-1828 [PMID:28218840] |
ChEMBL data shown on this page come from version 33:
Mendez D, Gaulton A, Bento AP, Chambers J, De Veij M, Félix E, Magariños MP, Mosquera JF, Mutowo P, Nowotka M, Gordillo-Marañón M, Hunter F, Junco L, Mugumbate G, Rodriguez-Lopez M, Atkinson F, Bosc N, Radoux CJ, Segura-Cabrera A, Hersey A, Leach AR. (2019) 'ChEMBL: towards direct deposition of bioassay data' Nucleic Acids Res., 47(D1). DOI: 10.1093/nar/gky1075. [EPMCID:30398643]
Davies M, Nowotka M, Papadatos G, Dedman N, Gaulton A, Atkinson F, Bellis L, Overington JP. (2015) 'ChEMBL web services: streamlining access to drug discovery data and utilities.' Nucleic Acids Res., 43(W1). DOI: 10.1093/nar/gkv352. [EPMCID:25883136]
